Page 46 - Mid Caps News Today

Hastings Technology Metals signs rare earth offtake contract with thyssenkrupp thyssenkrupp Materials Trading GmbH is expected to purchase 70,000 tonnes from Yangibana Rare Earths Project with prices referenced to the Asian Metals average 90-days ex-works price or at an agreed price between the parties. The offtake volume represents 60% of annual production volume for the first five years and 33% for the second five. Hastings Technology Metals Ltd (ASX:HAS) has executed a binding of...

Kazia Therapeutics licenses global rights to novel, first-in class, clinic-ready oncology drug candidate EVT801 Kazia expects to explore potential uses of EVT801 during the clinical program, including renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer) and soft tissue sarcoma. Evotec is a leading drug discovery and development company, headquartered in Hamburg, Germany, and listed on the Frankfurt Stock Exchange. Kazia Therapeutics Ltd (ASX:KZA) (FRA:NV9) (...

The group has appointed Rothschild & Co to undertake a review of some subsidiaries Grafton Group PLC (LON:GFTU) said it appointed advisor Rothschild & Co to undertake a review of some of its traditional merchanting businesses in the UK. The building materials distributor and DIY retailer said it may result in the sale of some or all of these subsidiaries. The review will focus on Buildbase, Civils & Lintels, PDM Buildbase, The Timber Group, Bathroom Distribution Group and NDI businesses. In the...

Perseus Mining annual golden goal of 500,000 ounces tracking “exceptionally well” The company has released its March quarterly report, which showed solid increases in both gold production and sales. There was a 29% increase in gold production and a nearly 4% decrease in all-in site costs. Perseus Mining Ltd (ASX:PRU) (TSE:PRU) (OTCMKTS:PMNXF) (FRA:P4Q) is on track to meet its target of producing 500,000 ounces of gold per annum, following a strong March quarter in which its seco...

Nicox Provides First Quarter 2021 Business Update and Financial Highlights NCX 470 Phase 3 trials in glaucoma on track for top-line results in top-line Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and financial highlights for Q1 2021 for Nicox SA and its subsidiaries (the "Nicox Group"), and updated key expected value-inflection milestones. Key Expected Milestones program in glaucoma : Nicoxs l...

Industrial relations are a hot-button issue in South Africa, but the rising vanadium price gives Bushveld room for manoeuvre

IS NOW APPROVED IN BRAZIL SOPHIA ANTIPOLIS, France, and LAVAL, Quebec, April 16, 2021 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), Bausch + Lomb, its leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Ag�...

Bausch Health Companies Inc. Bausch + Lomb, its leading global eye health business, and Nicox an international ophthalmology company, today announced that VYZULTA® 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency . VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other ...

Keeping it filtered: Why ESG does not qualify as a factor yet and why value still does Events If you already have an account please use the link below to sign in. If you have any problems with your access or would like to request an individual access account please contact our customer service team. Conscience, not return expectation, must drive portfolios Mark Northway of Sparrows Capital Mark Northway Factor investing is an approach that systematically targets specific, known, persistent driv...

Stocks that helped PMSes focused on smallcaps, midcaps outperform in March SECTIONS Share Synopsis Saurabh Mukherjea, Founder, Marcellus Investment Managers, thinks Indian specialty chemicals today is where the pharma sector stood in the mid-1990s -- on the cusp of a golden 20-year run. Getty Images Some multicap PMSes, which have larger allocation to midcap and smallcap stocks, also performed well in March, continuing from the earlier months. That was even when their benchmarks finished largel...